Valentis Advisors’ Jyotivardhan Jaipuria favors chemicals due to low dealer stocking and cement, anticipating benefits from consolidation and government demand. Pharma, particularly CDMO, shows growth potential, with US generics attractive on corrections. Small and mid-caps offer stronger earnings growth, but valuation is key. He remains cautious on alcobev due to fluctuating state policies.
Originally published by The Economic Times https://economictimes.indiatimes.com/markets